×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Brielle Urciuoli
A common goal for palliative care is pain management, where opioids like morphine are often on the frontline. Then, practitioners may build on medications from there, adding agents such as gabapentin and tricyclic antidepressants. But if those don’t work, Christopher J. Pietras, M.D. said that ketamine may be an option.
 
Kristie L. Kahl
Talazoparib reduced the risk for disease progression or death by 46 percent and improved quality of life compared with chemotherapy in a subgroup of women with breast cancer, according to the phase 3 EMBRACA trial results.
Jason M. Broderick
The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.
 
Kristie L. Kahl
CAR-T cell therapy has been showing promising in treating children with acute lymphoblastic leukemia, but it can come with significant toxicities. 
Brielle Urciuoli
While the treatment landscape of mantle cell lymphoma (MCL) has continued to evolve in recent years, researchers and clinicians alike are still at a loss for curative strategies. But immunotherapy may help.
Brielle Urciuoli
The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.
Katie Kosko
“What we really want this to do is be a place for patients to facilitate conversations with their doctor,” Michelle Woehrle, executive director of MPN Research Foundation (MPNRF) said.
Brielle Urciuoli
This is the first approval in the small cell lung cancer space in nearly two decades.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved Lenvima (lenvatinib) for the firstline treatment of patients with unresectable hepatocellular carcinoma (HCC).
Brielle Urciuoli
Researchers noted that melanoma diagnosis and treatment did not cause many women to put off becoming pregnant.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable